Advantage of autologous blood transfusion in surgery for hepatocellular carcinoma

Figure 1 Distribution of patients according to transfusion status during periods A and B. The proportion of patients who received HT was significantly lower in period B than period A (^aP < 0.0001). AT: Autologous transfusion; HT: Homologous transfusion.

Figure 2 Disease-free survival after curative surgery for hepatocellular carcinoma. A: There were no significant differences between the non-transfusion group (solid line) and the Autologous transfusion (AT) group (dotted line) (P = 0.3874); B: The cumulative disease-free survival in the non-Homologous transfusion (HT) group (solid line) was significantly better than in the HT group (dotted line) (^aP = 0.0305); C: The disease-free survival in the non-HT group (solid line) was significantly better in than the HT group (dotted line) in patients with maximum tumor size of ≤ 5.0 cm (^aP = 0.0452); D: No significant differences were noted between the non-HT group (solid line) and the HT group (dotted line) in patients with the maximum tumor size > 5.0 cm (P = 0.7391).